SPRB Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 110104 min ago

@ $4.51

Išleistas: 13 vas. 2024 @ 22:35

Grąža: -84.26%

Ankstesnis signalas: vas. 13 - 16:31

Ankstesnis signalas: Pirkimas

Grąža: 4.64 %

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 23:00):

Stats
Šios dienos apimtis	254 468
Vidutinė apimtis	1.36M
Rinkos kapitalizacija	29.22M
EPS	$0 ( 2024-03-21 )
Kita pelno data	( $-0.320 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.570
ATR14	$0.00100 (0.14%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-21	Novo Holdings A/s	Sell	465 021	COMMON STOCK
2024-03-18	Novo Holdings A/s	Sell	842 020	COMMON STOCK
2024-03-19	Novo Holdings A/s	Sell	593 000	COMMON STOCK
2024-03-20	Novo Holdings A/s	Sell	359 979	COMMON STOCK
2024-03-14	Novo Holdings A/s	Sell	1 912 316	COMMON STOCK

INSIDER POWER
2.63
Last 98 transactions
Buy: 11 294 782 \| Sell: 4 967 660

Tūris Koreliacija

Ilgas: 0.08 (neutral)

Trumpas: 0.20 (neutral)

Signal:(58.719) Neutral

Spruce Biosciences, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
DYNT	0.967
DGLY	0.954
FTFT	0.94
SLNO	0.94
SYKE	0.929
CVV	0.927
LIVE	0.925
CSWI	0.923
FELE	0.922
IPHA	0.921

10 Labiausiai neigiamai susiję koreliacijos
MTEX	-0.906
LCAP	-0.905
AHPI	-0.899
NAKD	-0.887
PROC	-0.883
LAWS	-0.88
VERA	-0.872
GRPH	-0.869
OP	-0.868
TRIT	-0.868

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Spruce Biosciences, Inc. Koreliacija - Valiuta/Žaliavos

-0.30
( neutral )

0.33
( neutral )

0.00
( neutral )

0.13
( neutral )

Spruce Biosciences, Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$10.09M
Bruto pelnas:	$10.02M (99.31 %)
EPS:	$-1.240

FY	2023
Pajamos:	$10.09M
Bruto pelnas:	$10.02M (99.31 %)
EPS:	$-1.240

FY	2022
Pajamos:	$0
Bruto pelnas:	$-429 000 (0.00 %)
EPS:	$-1.920

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.813

Financial Reports:

No articles found.

Spruce Biosciences, Inc.

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.